Cargando…

Pharmacoepigenetics in Heart Failure

Epigenetics studies inheritable changes of genes and gene expression that do not concern DNA nucleotide variation. Such modifications include DNA methylation, several forms of histone modification, and microRNAs. From recent studies, we know not only that genetic changes account for heritable phenot...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateo Leach, Irene, van der Harst, Pim, de Boer, Rudolf A.
Formato: Texto
Lenguaje:English
Publicado: Current Science Inc. 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875470/
https://www.ncbi.nlm.nih.gov/pubmed/20424992
http://dx.doi.org/10.1007/s11897-010-0011-y
_version_ 1782181580368773120
author Mateo Leach, Irene
van der Harst, Pim
de Boer, Rudolf A.
author_facet Mateo Leach, Irene
van der Harst, Pim
de Boer, Rudolf A.
author_sort Mateo Leach, Irene
collection PubMed
description Epigenetics studies inheritable changes of genes and gene expression that do not concern DNA nucleotide variation. Such modifications include DNA methylation, several forms of histone modification, and microRNAs. From recent studies, we know not only that genetic changes account for heritable phenotypic variation, but that epigenetic changes also play an important role in the variation of predisposition to disease and to drug response. In this review, we discuss recent evidence of epigenetic changes that play an important role in the development of cardiac hypertrophy and heart failure and may dictate response to therapy.
format Text
id pubmed-2875470
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Current Science Inc.
record_format MEDLINE/PubMed
spelling pubmed-28754702010-06-10 Pharmacoepigenetics in Heart Failure Mateo Leach, Irene van der Harst, Pim de Boer, Rudolf A. Curr Heart Fail Rep Article Epigenetics studies inheritable changes of genes and gene expression that do not concern DNA nucleotide variation. Such modifications include DNA methylation, several forms of histone modification, and microRNAs. From recent studies, we know not only that genetic changes account for heritable phenotypic variation, but that epigenetic changes also play an important role in the variation of predisposition to disease and to drug response. In this review, we discuss recent evidence of epigenetic changes that play an important role in the development of cardiac hypertrophy and heart failure and may dictate response to therapy. Current Science Inc. 2010-04-21 2010 /pmc/articles/PMC2875470/ /pubmed/20424992 http://dx.doi.org/10.1007/s11897-010-0011-y Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Mateo Leach, Irene
van der Harst, Pim
de Boer, Rudolf A.
Pharmacoepigenetics in Heart Failure
title Pharmacoepigenetics in Heart Failure
title_full Pharmacoepigenetics in Heart Failure
title_fullStr Pharmacoepigenetics in Heart Failure
title_full_unstemmed Pharmacoepigenetics in Heart Failure
title_short Pharmacoepigenetics in Heart Failure
title_sort pharmacoepigenetics in heart failure
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875470/
https://www.ncbi.nlm.nih.gov/pubmed/20424992
http://dx.doi.org/10.1007/s11897-010-0011-y
work_keys_str_mv AT mateoleachirene pharmacoepigeneticsinheartfailure
AT vanderharstpim pharmacoepigeneticsinheartfailure
AT deboerrudolfa pharmacoepigeneticsinheartfailure